Skip to main content Skip to section navigation Skip to footer
Investors Back To Corporate Site >

Journey Medical Corporation

  • Investors
  • Overview
  • Company
    • About Us
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock
    • Quote
    • Historical Data
  • Financials
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Analyst Coverage
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

NOW APPROVED

Journey Medical Corporation Announces the U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea.

Learn More

Press Releases

News & Events

News & Events

  • Press Releases
  • IR Calendar
May 7, 2025

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Apr 1, 2025

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Mar 26, 2025

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 24, 2025

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Mar 19, 2025

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Mar 12, 2025

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Mar 5, 2025

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Mar 4, 2025

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Jan 23, 2025

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Nov 12, 2024

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Journey Medical Corporation. All Rights Reserved.
Linkedin Logo Privacy Policy Terms of Use Sitemap

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

We use cookies to offer you a better browsing experience, including personalized advertising. By continuing to use the site you agree to their use.